AbbVie
ABBV
#25
Rank
NZ$942.58 B
Marketcap
NZ$533.25
Share price
-0.59%
Change (1 day)
28.87%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

EPS for AbbVie (ABBV)

EPS in 2026 (TTM): NZ$10.29

According to AbbVie's latest financial reports the company's current EPS (TTM) is NZ$10.66. In 2025 the company made an earnings per share (EPS) of NZ$4.31 a decrease over its 2024 EPS that were of NZ$4.41.

EPS history for AbbVie from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$10.29138.81%
2025NZ$4.31-2.26%
2024NZ$4.41-11.86%
2023NZ$5.00-58.95%
2022NZ$12.192.49%
2021NZ$11.90121.58%
2020NZ$5.37-44.7%
2019NZ$9.7145.84%
2018NZ$6.669.72%
2017NZ$6.07-9.54%
2016NZ$6.7116.28%
2015NZ$5.77184.1%
2014NZ$2.03-57.15%
2013NZ$4.74

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$1.29-87.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$56.26 427.90%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$31.65 197.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$4.30-59.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ-$5.65-152.98%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$8.23-22.76%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$12.97 21.68%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$5.24-50.83%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$12.69 19.11%๐Ÿ‡บ๐Ÿ‡ธ USA